Binnopharm Group's promoted drugs show growth in packs and rubles at the end of 2023

Binnopharm Group's promoted drugs showed growth in 2023. Alphaxim^® showed the highest growth in terms of market share in comparison with 2022, with a 17.4 % share in the addressable market at the end of December (+ 8.2 percentage points (p.p.) in roubles +11.9 p.p. in packs). Neobutin^® market share reached a record 24 % in packs (+ 3.8 p.p. vs 2022) and 21 % in terms of money (+3.5 p.p.). Kipferon^® demonstrated share growth by 4.7 p.p. in terms of roubles and by 2.5 p.p. in packs. The drug's share in the addressable market in December amounted to 35.9 % in terms of roubles and 16.6 % in units. Venaproct-ALIUM showed active growth - sales in packs and in money terms increased 8 times compared to 2022. 


Anton Fedosyuk, Marketing Director of Binnopharm Group: "The 2023 data show that our drugs are not just competitive, but are becoming more and more in demand among consumers every year. Thanks to competent omnichannel promotion, work with target audiences and the ability to offer high-quality drugs to the market, the share of Binnopharm Group brands is growing in the market. According to the results of 2023, there is not a single drug among the promoted drugs of the company that has decreased sales in monetary terms. At the same time, the potential of Binnopharm Group's portfolio has not been fully revealed yet, we see growth areas".